Lastest Paronychia News

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results – Earnings
Inhibition of wild-type EGFR is associated with cutaneous toxicities such as rash, stomatitis and paronychia, all of which may significantly impact patients' quality of life, can result in treatment discontinuation and can cause patient distress. We …
Read more on Seeking Alpha (registration)

Boehringer Ingelheim and CureVac announce collaboration to develop next
… common adverse reactions in the pivotal study (greater than or equal to 20% all grades & vs pemetrexed/cisplatin-treated patients (n=111)) were diarrhea (96% vs 23%), rash/dermatitis acneiform (90% vs 11%), stomatitis (71% vs 15%), paronychia (58 …
Read more on MarketWatch

Comments are closed.

Scroll to Top